Cure Pharmaceutical Holding Corp. CURR
We take great care to ensure that the data presented and summarized in this overview for Cure Pharmaceutical Holding Corp. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CURR
Top Purchases
Top Sells
About CURR
CURE Pharmaceutical Holding Corp., a biopharmaceutical company, focuses on the development and manufacturing of drug formulation and drug delivery technologies to enhance drug safety, efficacy, and patient adherence. It operates through two segments, Cure and Sera Labs. The company's pharmaceutical drug programs include CUREfilm Blue, a sildenafil oral thin film (OTF) for the treatment of erectile dysfunction; CUREfilm Canna, a cannabinoid product with optimized pharmacokinetic profiles using microCURE and CUREfilm technology; CUREfilm Anti-Viral, an orally bio-available anti-viral of an existing therapeutic leveraging existing pre-clinical/clinical safety and toxicity data; and CUREfilm Central Nervous System, a novel dosage form to treat mental health disorders, such as depression, PTSD, addiction disorders, obsessive compulsive disorders, and anxiety. It also sells various wellness products under its distribution partners' brands. In addition, the company develops 50,000IU and Vitamin D3 OTF for oral administration. It has a licensing agreement with Canopy Growth Corporation. The company was founded in 2011 and is headquartered in Oxnard, California.
Insider Transactions at CURR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 23
2022
|
Gene Z Salkind |
BUY
Exercise of conversion of derivative security
|
Direct |
117,647
+50.0%
|
$0
$0.26 P/Share
|
Aug 12
2022
|
Robert J Costantino |
BUY
Grant, award, or other acquisition
|
Direct |
226,764
+19.21%
|
-
|
Jul 25
2022
|
Gerald Bagg |
BUY
Grant, award, or other acquisition
|
Direct |
220,795
+50.0%
|
-
|
Jul 25
2022
|
Robert Steven Davidson |
BUY
Grant, award, or other acquisition
|
Direct |
220,795
+14.68%
|
-
|
Jul 22
2022
|
Robert Steven Davidson |
BUY
Grant, award, or other acquisition
|
Direct |
500,000
+32.0%
|
-
|
May 27
2021
|
Jonathan Berlent Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+50.0%
|
$0
$0.69 P/Share
|
May 25
2021
|
Nancy Duitch Chief Strategy Officer |
BUY
Open market or private purchase
|
Indirect |
1,000
+0.02%
|
$0
$0.7 P/Share
|
May 24
2021
|
Robert Steven Davidson |
BUY
Open market or private purchase
|
Direct |
6,443
+1.13%
|
$0
$0.69 P/Share
|
May 21
2021
|
Nancy Duitch Chief Strategy Officer |
BUY
Open market or private purchase
|
Indirect |
5,000
+0.1%
|
$0
$0.74 P/Share
|
May 21
2021
|
Robert Steven Davidson |
BUY
Open market or private purchase
|
Direct |
7,400
+1.33%
|
$0
$0.71 P/Share
|
Dec 18
2020
|
Robert Steven Davidson |
BUY
Open market or private purchase
|
Direct |
6,887
+0.42%
|
$6,887
$1.44 P/Share
|
Aug 20
2020
|
John K Bell |
BUY
Grant, award, or other acquisition
|
Direct |
17,601
+50.0%
|
-
|
Aug 19
2020
|
Gene Z Salkind |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+3.62%
|
-
|
Aug 06
2020
|
Anna Goldin |
BUY
Grant, award, or other acquisition
|
Direct |
21,579
+50.0%
|
-
|
Aug 06
2020
|
Lauren Chung |
BUY
Grant, award, or other acquisition
|
Direct |
21,579
+50.0%
|
-
|
Jun 05
2020
|
Joshua Held |
BUY
Grant, award, or other acquisition
|
Indirect |
2,106,315
+33.44%
|
-
|
Jul 01
2019
|
Robert Steven Davidson |
BUY
Grant, award, or other acquisition
|
Direct |
31,250
+5.32%
|
-
|
Feb 15
2019
|
Gene Z Salkind |
BUY
Grant, award, or other acquisition
|
Direct |
1,621,877
+46.42%
|
-
|
Jan 01
2019
|
Gene Z Salkind |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+50.0%
|
-
|
Oct 10
2018
|
Robert Steven Davidson |
SELL
Bona fide gift
|
Direct |
25,000
-4.55%
|
-
|